|
| EDITORIAL |
|
|
|
| Year : 2006 | Volume
: 38
| Issue : 3 | Page : 169-170 |
| |
Irrational drug combinations: Need to sensitize undergraduates
CS Gautam, S Aditya
Department of Pharmacology, GMCH, Chandigarh - 160 032, India
Correspondence Address:
S Aditya
Department of Pharmacology, GMCH, Chandigarh - 160 032
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.25802
How to cite this article:
Gautam C S, Aditya S. Irrational drug combinations: Need to sensitize undergraduates. Indian J Pharmacol 2006;38:169-70 |
Prescribing fixed dose drug combinations has become the "in thing" in medical practice. Using the excuse of better patient compliance, many doctors, both in private as well as government prescribe irrational fixed dose drug combinations. Quite a few infectious diseases are becoming resistant to treatment with a single drug. With the escalating cost of drugs, there is poor drug compliance, which further magnifies the problem, both for the prescriber as well the patient. Manufacturers of drugs having quickly tuned in to the potential golden egg, are marketing fixed dose drug formulations for various diseases.
Even though use of combinations of drugs is common practice, the selection of optimal dose and optimal combination has remained largely a matter of trial and error. The basis of many fixed dose drug combinations being taught to the undergraduate medical students and also being prescribed popularly, appears to be irrational to pharmacologists.
CIMS lists more than 100 irrational combinations which are not approved in any developed country but are being marketed in India. This fact has to be taught to undergraduate medical students in their formative years of learning so that once they address medical ailments like malaria, tuberculosis, AIDS, hypertension, etc. they should be more logical in selecting appropriate drug combinations and should not be swayed by marketing tricks and false claims made by the pharmaceutical industry. The pharmacological basis of combining each ingredient in the formulation should be taught. Selection of P drugs, rational drug use, use of rational drug combinations and ethical laboratory practices should be inculcated in the student's curriculum during their clinical training.
Fourteenth WHO model list of essential medicines (March 2005) contains only 18 approved drug combinations, whereas in India, there are innumerable examples of irrational drug combinations, which are easily available and can be bought without necessarily giving a prescription. [Table - 1] This issue has to be urgently addressed by us, pharmacologists, as the magnitude of the problem is increasing.
What needs to be done?
1. The hit and trial method of combining drugs should be replaced by a rational and logical basis for bringing out a fixed dose drug formulation. Operational, statistical and mathematical models constitute a highly versatile framework for mechanism based modeling (pharmacokinetic/ pharmacodynamic) by taking signal transduction properties of the drug combination into account. Sound scientific research should underlie the development and production of drug combinations.
2. There is a need to carefully monitor and censor misleading claims by the pharmaceutical industry. Some degree of irresponsibility on the part of the pharmaceutical industry and lack of vigilance of government agencies underlies the increased popularity of irrational drug combinations. Most advertisements in many of the medical journals published from India fail to mention important details pertaining to correct usage of drug combinations. Clinical pharmacists can play an important role in guiding and imparting knowledge to the public.
3. There is a need to strengthen the mechanism for continuing professional development of practitioners to ensure that they have the necessary knowledge and skills to prescribe rationally. Perhaps the insistence that prescribers, especially those in private practice should undergo a continuing medical education (CME) course once in two years on newer drug combinations, new drug molecules introduced into the market and adverse drug reactions will go a long way in curbing irrational prescribing.
4. ADR reporting should be made mandatory as they are in developed countries. Pharmacovigilance should be more effective.
5. Hospitals should constitute drugs and therapeutics review committees to rationalize prescribing.
6. Finally, medical schools and postgraduate colleges must take the responsibility of training students and young doctors how to assess new drug combinations more logically.
Unless we encourage our students to think rationally and independently this menace will continue to grow. We cannot complacently offload all blame onto the industry and government regulators; the onus of responsibility lies heavily on the shoulders of academicians too[3].
| References | |  |
| 1. | Satoskar RS. The expanding role of pharmacologist in the changing Indian scene. J Postgrad Med 1986;32:111-3.  |
| 2. | Jonker DM, Visser SA, Vander Graaf PH, Voskuyl RA, Danhof M. Towards a mechanism based analysis of pharmacodynamic drug-drug interactions. Pharmacol Ther 2005;106:1-18. |
| 3. | Shenfield G. Prescribers and drug withdrawals. Aus Prescr 2005;28:54-55. |
Tables
[Table - 1]
| This article has been cited by | | 1 |
Newer FDCs in Indian Market are they Rational or Irrational |
|
| Sandeep Kharkar | | Vidarbha Journal of Internal Medicine. 2023; 33: 1 | | [Pubmed] | [DOI] | | | 2 |
Ofloxacin/ tinidazole induced fixed drug eruption- a case report |
|
| Monika Kapoor | | Journal of Pharmacovigilance and Drug Research. 2021; 2(1): 36 | | [Pubmed] | [DOI] | | | 3 |
Prescribing Pattern of Drugs in the Geriatric Patients in Jazan Province, KSA |
|
| Nakul Gupta | | Pharmacy & Pharmacology International Journal. 2015; 2(1) | | [Pubmed] | [DOI] | | | 4 |
Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009 |
|
| Veronika J. Wirtz,Peter G. M. Mol,Jonneke Verdijk,Robert H. Vander Stichele,Katja Taxis | | Tropical Medicine & International Health. 2013; 18(4): 416 | | [Pubmed] | [DOI] | | | 5 |
Sensitive LC-ESI/MS/MS assay for the quantification and pharmacokinetic study of roxithromycin in human serum |
|
| Yu Xu,Na Li,Yanan Luo,Junjie Sun,Bo Jiang,Qingxiang Guo | | Journal of Analytical Chemistry. 2013; 68(8): 743 | | [Pubmed] | [DOI] | | | 6 |
What does the growing prominence of Asia mean for pharmaceutical safety management? |
|
| Stewart Geary | | Future Medicinal Chemistry. 2010; 2(10): 1503 | | [VIEW] | [DOI] | | | 7 |
Comparison of analgesic effects of nimesulide, paracetamol, and their combination in animal models |
|
| Ahmed, M., Upadhyaya, P., Seth, V. | | Indian Journal of Pharmacology. 2010; 42(6): 354-357 | | [Pubmed] | | | 8 |
What does the growing prominence of Asia mean for pharmaceutical safety management? |
|
| Geary, S. | | Future Medicinal Chemistry. 2010; 2(10): 1503-1506 | | [Pubmed] | | | 9 |
Prevalence of fixed dose drug combinations in nepal: A preliminary study |
|
| Poudel, A., Subish, P., Mishra, P., Mohamed Izham, M.I., Jayasekera, J. | | Journal of Clinical and Diagnostic Research. 2010; 4(2): 2246-2252 | | [Pubmed] | | | 10 |
Regulatory status of banned drugs in India |
|
| Shaji, J., Lodha, S. | | Indian Journal of Pharmaceutical Education and Research. 2010; 44(1): 86-94 | | [Pubmed] | | | 11 |
Irrational fixed dose combinations in Nepal: Need for intervention |
|
| Poudel, A., Palaian, S., Shankar, P.R., Jayasekera, J., Izham, M.I.M. | | Kathmandu University Medical Journal. 2008; 6(23): 399-405 | | [Pubmed] | | | 12 |
Fixed dose drug combinations (FDCs): Rational or irrational: A view point |
|
| Gautam, C.S., Saha, L. | | British Journal of Clinical Pharmacology. 2008; 65(5): 795-796 | | [Pubmed] | | | 13 |
Is the combination of enalapril and losartan irrational? |
|
| Parmar, D., Jadav, S. | | Indian Journal of Pharmacology. 2008; 40(2): 91 | | [Pubmed] | | | 14 |
Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS |
|
| Hang, T.-j., Zhang, M., Song, M., Shen, J.-p., Zhang, Y.-d. | | Clinica Chimica Acta. 2007; 382((1-2)): 20-24 | | [Pubmed] | | | 15 |
Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS |
|
| Tai-jun Hang,Meng Zhang,Min Song,Jian-ping Shen,Yin-di Zhang | | Clinica Chimica Acta. 2007; 382(1-2): 20 | | [Pubmed] | [DOI] | | | 16 |
Combined treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARB): æBeating a dead horseæ or meaningful mechanism-guided therapy? |
|
| Petroianu, G.A. | | Indian Journal of Pharmacology. 2006; 38(5): 372-373 | | [Pubmed] | |
|
|
|
|
|
|
|
|
